The U.S. Capitol dome is illuminated as the House of Representatives returns to Washington to vote to reopen the government Wednesday, Nov. 12, 2025.Private markets could get an influx of capital and investors under legislation approved by the House on ThursdayThe package of capital-formation bills, called the INVEST Act, passed the House 302 to 123. Eighty-seven Democrats joined every Republican in the House to support the bill. The wide-ranging package of legislation would allow more investors access to p ...

Core Insights - Siebert Financial Corp. has opened a new office in Washington, D.C. to enhance its Capital Markets and Investment Banking operations [1][2] - The new office aims to strengthen relationships with policy, regulatory, and industry stakeholders, aligning with opportunities from new administration initiatives [2][3] Company Expansion - The Washington, D.C. office is located at 3000 K Street, N.W., Suite 245 and will be led by Daniel M. Ondeck, Head of Institutional Sales, and Brandon Fry, Managing Director, Debt Sales [1] - This expansion is part of Siebert's strategy to be closer to decision-makers in the capital, facilitating faster responses to market changes [3] Strategic Focus - The D.C. team will collaborate with colleagues in New York and Miami to support issuance, private placements, and structured solutions for corporate and institutional clients [3] - The focus will be on origination, disciplined distribution, and consistent coverage for issuers and investors, translating policy signals into actionable capital solutions [3]

Core Insights - The SEC has appointed James J. Moloney as the new director of the Division of Corporation Finance, effective next month, with a focus on enhancing corporate governance and disclosure practices [8] - The leadership change aligns with the SEC's shift in priorities under President Trump, moving towards a less aggressive regulatory stance, particularly in areas like cryptocurrency [4][7] - Moloney brings extensive experience from his previous tenure at the SEC and his long career at Gibson Dunn, where he specialized in corporate governance, disclosure rules, and mergers and acquisitions [5][6] Division of Corporation Finance - The Division of Corporation Finance is responsible for ensuring that investors receive necessary information for informed investment and voting decisions, particularly during public offerings and ongoing disclosures [3] - The division selectively reviews documents filed by companies during public offerings, business combinations, and proxy solicitations to uphold transparency [3] Leadership and Regulatory Focus - SEC Chairman Paul Atkins emphasized Moloney's extensive experience and understanding of corporate governance, indicating a supportive approach towards innovation and capital formation [8] - Moloney expressed his commitment to developing a clear regulatory framework that benefits both companies and investors, highlighting the need for practical and effective regulations [6]

Core Insights - NeOnc Technologies Holdings, Inc. has achieved a significant milestone by executing a Sub-License Agreement with its Abu Dhabi subsidiary, NuroCure, covering the UAE and wider GCC and MENA region for its therapeutics NEO100 and NEO212 [1][2] - The company is progressing towards a strategic partnership with Quazar Investment, which includes a potential $50 million equity investment aimed at expanding operations in the MENA region [2][5] - NeOnc's inclusion in the Russell Microcap Index is strategically timed with the Quazar partnership to attract institutional capital and enhance market liquidity [3] Company Developments - The Sub-License Agreement is the second of five required conditions for closing the transaction with Quazar, indicating progress in the partnership [2][5] - The proposed capital formation round led by Quazar is priced at $25 per share, with 70% of proceeds allocated for acquiring NeOnc common stock and 30% for clinical trials and infrastructure development in the MENA region [5] - NeOnc's NEO100 and NEO212 therapeutics are currently in Phase II clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status, showcasing the company's commitment to advancing life-saving therapies [6] Strategic Goals - The completion of the Sub-License Agreement is viewed as a critical step in unlocking the full potential of the $50 million partnership, aimed at delivering long-term value to shareholders [4] - The company is undergoing a transformation from a clinical-stage biotech to a global brain cancer platform, as noted by industry experts [4] - NeOnc has an extensive patent portfolio licensed from the University of Southern California, which supports its drug development efforts and extends patent protections to 2038 [6]

Industry Trends - Onchain trading, capital formation, and payments are approaching a point where they offer superior products compared to offchain alternatives [1] - The industry anticipates rapid changes once the threshold of onchain solutions surpassing offchain options is crossed [1]